Our analysis revealed that Plek2 expression levels were indicative of how mouse models of 4T1, T22 (mammary cancer), and CT26 (colorectal carcinoma) responded to immunotherapy treatments targeting PD-L1 and CTLA-4 (Fig. 6b). The gene discussed is PLEK2; the disease is colorectal carcinoma.